Generic Name: latanoprost
Brand Name: Monoprost
Manufacturer: Laboratoires Théa
Therapeutic Area: glaucoma and ocular hypertension
Indications: glaucoma and ocular hypertension
Submission Type: Initial
Project Status: Complete
Biosimilar: No
Date Recommendation Issued: April 24, 2018
Recommendation Type: Reimburse with clinical criteria and/or conditions
Fee Schedule: Schedule A
Key Milestones2 | |
---|---|
Call for patient input posted | September 26, 2017 |
Patient group input closed | November 15, 2017 |
Clarification: - No patient input submission received | |
Submission received | October 25, 2017 |
Submission accepted for review | November 08, 2017 |
Review initiated | November 09, 2017 |
Draft CDR review report(s) sent to applicant | February 01, 2018 |
Comments from applicant on draft CDR review report(s) received | February 12, 2018 |
Redaction requests from applicant on draft CDR review report(s) received | February 20, 2018 |
CDR review team's comments on draft CDR review report(s) sent to applicant | March 09, 2018 |
Canadian Drug Expert Committee (CDEC) meeting | March 21, 2018 |
CDEC recommendation & redacted CDR review report(s) sent to applicant and drug plans | April 03, 2018 |
Embargo period ended and validation of redacted CDR review report(s) received | April 17, 2018 |
CDEC Final Recommendation issued to applicant and drug plans | April 24, 2018 |
CDEC Final Recommendation posted | April 27, 2018 |
Final CDR review report(s) and patient input posted | May 17, 2018 |